We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-25.07%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$28M
(-18%)
Cap. Flow
+$4.28M
Cap. Flow
% of AUM
3.37%
Top 10 Holdings %
Top 10 Hldgs %
74.71%
Holding
39
New
7
Increased
11
Reduced
6
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KZR
Kezar Life Sciences
KZR
|
+$8.49M |
| 2 |
ONEM
1Life Healthcare
ONEM
|
+$6.23M |
| 3 |
MeiraGTx Holdings
MGTX
|
+$5.87M |
| 4 |
Tenet Healthcare
THC
|
+$3.53M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
|
+$4.89M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$3.71M |
| 3 |
Agilon Health
AGL
|
+$3.55M |
| 4 |
Encompass Health
EHC
|
+$2.84M |
| 5 |
Oscar Health
OSCR
|
+$2.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.28% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $20.6M | 16.22% |
369,000
-5,000
| -1% | -$296K |
|
2
Prothena Corp
PRTA
$458M
| $14.9M | 11.77% |
550,000
-16,538
| -3% | -$484K |
|
|
KZR
3
DELISTED
Kezar Life Sciences
KZR
| $10.4M | 8.23% |
126,269
+96,269
| +321% | +$8.49M |
|
|
ALBO
4
DELISTED
Albireo Pharma Inc
ALBO
| $9.29M | 7.32% |
467,795
-12,205
| -3% | -$322K |
|
|
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
| $8.08M | 6.36% |
820,752
+231,482
| +39% | +$2.55M |
|
6
Aldeyra Therapeutics
ALDX
$91.7M
| $7.92M | 6.24% |
1,985,883
+585,644
| +42% | +$2.01M |
|
|
7
MeiraGTx Holdings
MGTX
$1.09B
| $7.47M | 5.88% |
986,218
+605,518
| +159% | +$5.87M |
|
8
Charles River Laboratories
CRL
$10.9B
| $5.88M | 4.64% |
27,500
-4,000
| -13% | -$977K |
|
|
ONEM
9
DELISTED
1Life Healthcare
ONEM
| $5.68M | 4.48% |
+725,000
| New | +$6.23M |
|
10
QuidelOrtho
QDEL
$1.09B
| $4.53M | 3.57% |
46,576
+20,901
| +81% | +$2.13M |
|
11
Shattuck Labs
STTK
$710M
| $4.14M | 3.26% |
1,020,000
+221,282
| +28% | +$801K |
|
12
Cue Biopharma
CUE
$135M
| $4.12M | 3.25% |
55,183
+4,840
| +10% | +$566K |
|
13
Rocket Pharmaceuticals
RCKT
$348M
| $3.81M | 3% |
276,802
+73,534
| +36% | +$877K |
|
|
ONEM
14
CALL
DELISTED
1Life Healthcare
ONEM
| $3.45M | 2.72% |
+440,000
| New | +$3.78M |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.25M | 2.56% |
+101,847
| New | +$2.98M |
|
16
Mirum Pharmaceuticals
MIRM
$6.89B
| $3.14M | 2.48% |
161,527
+87,597
| +118% | +$2.07M |
|
|
17
Tenet Healthcare
THC
$20.1B
| $2.67M | 2.1% |
+50,700
| New | +$3.53M |
|
18
BioCryst Pharmaceuticals
BCRX
$2.37B
| $1.87M | 1.47% |
+176,680
| New | +$1.82M |
|
19
ARS Pharmaceuticals
SPRY
$590M
| $1.45M | 1.14% |
341,108
+15,743
| +5% | +$54.9K |
|
20
ProQR Therapeutics
PRQR
$243M
| $1.33M | 1.05% |
1,707,509
+1,108,221
| +185% | +$826K |
|
21
Ardelyx
ARDX
$1.24B
| $1.28M | 1.01% |
+2,163,520
| New | +$1.59M |
|
22
InMode
INMD
$872M
| $1.01M | 0.79% |
45,000
-5,000
| -10% | -$131K |
|
|
APEN
23
DELISTED
Apollo Endosurgery, Inc.
APEN
| $329K | 0.26% |
+90,176
| New | +$426K |
|
24
Cognition Therapeutics
CGTX
$82.3M
| $254K | 0.2% |
120,198
-119,882
| -50% | -$310K |
|
|
25
Agilon Health
AGL
$1.64B
| – | – |
-5,600
| Closed | -$3.55M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q2 2022 Portfolio in Review
As of Q2 2022, Prosight Management held 39 positions worth $127M, down 18% from $155M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Prosight Management deployed $4.28M of net new capital in Q2 2022, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was 1Life Healthcare: 725,000 shares worth $5.68M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Charles River Laboratories, an estimated $977K trimmed.
- Prosight Management's largest Q2 2022 buy was 1Life Healthcare: 725,000 shares worth $5.68M.
- Prosight Management added most to Kezar Life Sciences in Q2 2022, an estimated $8.49M increase.
- Prosight Management's biggest Q2 2022 reduction was Charles River Laboratories, cutting an estimated $977K.
- Prosight Management fully exited Convey Health Solutions Holdings, Inc. in Q2 2022, selling an estimated $4.89M.
- Prosight Management's ten largest holdings make up 75% of its $127M portfolio in Q2 2022.
- Prosight Management opened 7 new positions and closed 15 in Q2 2022.
- Prosight Management's portfolio value fell 18% quarter-over-quarter to $127M.
Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.